Albeit we performed a systemic immunohistology screening for Trop2, our study has limitations, since there remains a residual risk of a potential selection bias of the used DLBCL samples gained from a single center cohort. The gene discussed is TACSTD2; the disease is diffuse large B-cell lymphoma.